Last reviewed · How we verify

Gwo Xi Stem Cell Applied Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

Gwo Xi Stem Cell Applied Technology Co., Ltd. pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams Maternity Hospital · 1 shared drug class
  2. Gary A Levy, O. Ont. MD. FRCP AGAF · 1 shared drug class
  3. Manipal Acunova Ltd. · 1 shared drug class
  4. Mesoblast, Inc. · 1 shared drug class
  5. Nature Cell Co. Ltd. · 1 shared drug class
  6. Tigenix S.A.U. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gwo Xi Stem Cell Applied Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Gwo Xi Stem Cell Applied Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gwo-xi-stem-cell-applied-technology-co-ltd. Accessed 2026-05-16.

Related